Pancreatic carcinoma in perspective: A continuing challenge

Cancer

Volumn 78, Issue 3 SUPPL., 1996, Pages 580-591

  Wanebo, Harold J ^a   Vezeridis, Michael P ^a  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

ERCP; management; pancreatic cancer; pathobiology

Indexed keywords

CANCER RISK; CANCER SURVIVAL; CHRONIC PANCREATITIS; HUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING;

HUMANS; PANCREATIC NEOPLASMS;

EID: 0029954462     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960801)78:3<580::AID-CNCR38>3.0.CO;2-T     Document Type: Review

References (181)

1. Boring CC, Squires ITS, Tong T, Montgomery BA. Cancer Statistics 1994. Atlanta: American Cancer Society, 1994.
2. Ahlgren JD, Hill MC, Roberts IM. Pancreatic cancer: patterns, diagnosis and approaches to treatment. In: Ahlgren JD, McDonald JS (editors). Gastrointestinal oncology. Philadelphia: JB Lippincott, 1992:197-207.
3. Warshaw AL, Fernandez-DelCastillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
4. Vezeridis MP, Wanebo HJ. Pancreatic cancer. RI Med J 1994;77:115-8.
5. Doll R, Peto R. Mortality in relation to smoking: 20 years observations on male British doctors. BMJ 1976;2:1525-36.
6. Mack TM, Yu MC, Hanich R, Henderson BE. Pancreas cancer and smoking, beverage consumption, and past medical history. J Natl Cancer Inst 1986;76:49-60.
7. Falk RT, Pickle LW, Fontham ET, Correa P, Fraumeni JF Jr. Life-style risk factors for pancreatic cancer in Louisiana: a case-control study. Am J Epidemiol 1988;128:324-36.
8. Cuzick J, Babiker AG. Pancreatic cancer, alcohol, diabetes mellitus and gall-bladder disease. Int J Cancer 1989;43:415-21.
9. Farrow DC, Davis S. Risk of pancreatic cancer in relation to medical history and the use of tobacco, alcohol and coffee. Int J Cancer 1990;45:816-20.
10. Ghadirian P, Simard A, Baillargeon J. Tobacco, alcohol and coffee and cancer of the pancreas. Cancer 1991;67:2664-70.
11. Hirayama T. Epidemiology of pancreatic cancer in Japan. Jpn J Clin Oncol 1989;19:208-15.
12. Howe GR, Jain M, Burch JD, Miller AB. Cigarette smoking and cancer of the pancreas: evidence from a population-based case-control study in Toronto, Canada. Int J Cancer 1991;47:323-8.
13. Rivenson A, Hoffmann D, Prokopczyk B, Prokopczyk B, Amin S, Hecht SS. Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. Cancer Res 1988;48:6912-17.
14. Norell SE, Ahlbom A, Erwald R, Jacobson G, Lindberg-Navier I, Olin R, et al. Diet and pancreatic cancer: a case-control study. Am J Epidemiol 1986;124:894-902.
15. Mills PK, Beeson WL, Abbey DE, Fraser GE, Phillips RL. Dietary habits and past medical history as related to fatal pancreas cancer risk among Adventists. Cancer 1988;61:2578-85.
16. Farrow DC, Davis S. Diet and the risk of pancreatic cancer in men. Am J Epidemiol 1990;132:423-31.
17. Birt DF, Stepan KR, Pour PM. Interaction of dietary fat and protein on pancreatic carcinogenesis in Syrian golden hamsters. J Natl Cancer Inst 1983;71:355-60.
18. Longnecker DS, Roebuck BD, Kuhlmann ET. Enhancement of pancreatic carcinogenesis by a dietary unsaturated fat in rats treated with saline or N-nitroso (2-hydroxypropyl) (2-oxopropyl)amine. J Natl Cancer Inst 1985;74:219-22.
19. MacMahon B, Yen S, Trichopoulos D, Warren K, Nardi G. Coffee and cancer of the pancreas. N Engl J Med 1981; 304:630-3.
20. Feinstein AR, Horowitz RI, Spitzer WO, Battista RN. Coffee and pancreatic cancer: the problems of etiologic science and epidemiologic case control research. JAMA 1981;246:957-61.
21. Wynder E, Hall N, Polansky M. Epidemiology of coffee and pancreatic cancer. Cancer Res 1983;43:3900-6.
22. Gordis L. Consumption of methylxanthine-containing beverages and risk of pancreatic cancer. Cancer Lett 1990;52:1-12.
23. Hakulinen T, Lehtimaki L, Lehtonen M, Teppo L. Cancer morbidity among two male cohorts with increased alcohol consumption in Finland. J Natl Cancer Inst 1974;52:1711-4.
24. Wynder E, Maabuchi K, Maruchi N, Fortner JG. Epidemiology of cancer of the pancreas. J Natl Cancer Inst 1973; 50:645-67.
25. Monson R, Lyon J. Proportional mortality among alcoholics. Cancer 1975;36:1077-9.
26. Zheng W, McLaughlin JK, Gridley G, Bjele E, Schuman LM, Silverman DT, et al. A cohort study of smoking, alcohol consumption, and dietary factors for pancreatic cancer (United States). Cancer Causes Control 1993;4:477-82.
27. Guralnik L. Mortality by occupational level and cause of death. Vital statistics special reports 53(5). Washington, DC: U.S. Department of Health, Education, and Welfare, 1963.
28. Redmond CK, Strobino BR, Cypess RH. Cancer experience among coke by-product workers. Ann NY Acad Sci 1976; 271:102-15.
29. Milham S Jr. Neoplasia in the wood and pulp industry. Ann NY Acad Sci 1976;271:294-300.
30. Mancuso TF, el-Attar AA. Cohort study of workers exposed to betanaphthylamine and benzidine. J Occup Med 1967; 9:277-85.
31. Lin RS, Kessler II. A multifactorial model for pancreatic cancer in man. JAMA 1981;245:147-52.
32. Bartholomew L, Gross J. Carcinoma of the pancreas associated with chronic relapsing pancreatitis. Gastroenterology 1958;35:473-7.
33. Moehr P, Ammann R, Lasgiader F, et al. Pankreaskarzinom bei chronischer Pankreatitis. Schweiz Med Wochenschr 1975;105:590-2.
34. Girard RM, Dube S, Archambault AP. Hereditary pancreatitis: report of an affected Canadian kindred and review of the disease. Can Med Assoc J 1981;125:576-80.
35. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Anderson JR, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med 1993;328:1433-7.
36. Gold E, Cameron JL. Chronic pancreatitis and pancreatic cancer. N Engl J Med 1993;328:1485-6.
37. Lin A, Feller ER. Pancreatic carcinoma as a cause of unexplained pancreatitis: report of ten cases. Ann Intern Med 1990;113:166-7.
38. Ekbom A, McLaughlin JK, Marlson BM, Britt-Marie K, Nyren O, Gridley G, et al. Pancreatitis and pancreatic cancer: a population based study. J Natl Cancer Inst 1994;86:625-7.
39. Luzick J, Babiker AG. Pancreatic cancer, alcohol, diabetes mellitus and gallbladder disease. Int J Cancer 1989;43:415-21.
40. Sasaki A, Kamado K, Horiuchi N. A changing pattern of causes of death in Japanese diabetics: observations over fifteen years. J Chron Dis 1978;31:433-44.
41. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnquist HJ, Larsson J. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993;80:1047-55.
42. Morohoshi T, Held G, Kloppel G. Exocrine pancreatic tumors and their histological classification: a study based on 167 autopsy and 97 surgical cases. Histopathology 1983;7:645-61.
43. Cubilla AL, Fitzgerald PJ. Tumors of the exocrine pancreas. Atlas of tumor pathology. 2nd series. Fascicle 19. Washington DC: Armed Forces Institute of Pathology, 1984.
44. Compagno J, Oertel JE. Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadeno-carcinoma and cystadenoma): a clinico-pathologic study of 41 cases. Am J Clin Pathol 1978;69:573-80.
45. Sanfey H, Mendelsohn G, Cameron JL. Solid and papillary neoplasms of the pancreas: a potentially curable surgical lesion. Ann Surg 1983;197:272-5.
46. Matsanou H, Konishi F. Papillary-cystic neoplasms of the pancreas: a clinicopathologic study concerning the tumor aging and malignancy of nine cases. Cancer 1990;64:283-91.
47. Bottger TC, Storkel S, Wellek S, Stockle M, Junginger T. Factors influencing survival after resection of pancreatic cancer: a DNA analysis and a histomorphic study. Cancer 1994; 73:63-73.
48. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165:68-72.
49. Redston MS, Caldas C, Seymour AB, Hruban RH, DaCosta L, Yeo CJ, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994;54:3025-33.
50. Berrozpe G, Schaeffer J, Peinado MA, Real FX, Perucho M. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer 1994;58:185-91.
51. Hruban RH, can Mansfield A, Offerhaus GJ, vanWeering DHJ, Allison DC, Goodman xx. K-ras oncogene activation in adenocarcinoma of the human pancreas. Am J Pathol 1993;143:545-55.
52. Urban T, Ricci S, Grange JD, Lacave R, Boudghene F, Breittmayer F, et al. Detection of C-K-ras mutation by PCR/RFLP analysis and diagnosis of pancreatic adenocarcinomas. J Natl Cancer Inst 1993;85:2008-12.
53. Yanagisawa A, Ohtake K, Ohashi K, Hori O, Kitagawa T, Sugano H, et al. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflamation. Cancer Res 1993;53:953-6.
54. Fearon ER. K-ras gene mutation as a pathogenic and diagnostic marker in human cancer. J Natl Cancer Inst 1993; 85:1978-9.
55. Friess H, Yamanaha Y, Buchler M, Ebert M, Beger HG, Gold LI, et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993;105:1846-56.
56. Friess H, Yamanaha Y, Buchler M, Korbin MS, Tahara E, Korc M. Cripto, a member of epidermal growth factor family, is over-expressed in human pancreatic cancer and chronic pancreatitis. Int J Cancer 1994;56:668-74.
57. Nagai H, Kuroda A, Morioka Y. Lymphatic and local spread of T1 and T2 pancreatic cancer. Ann Surg 1986;204:65-71.
58. Nagakawa T, Kobayashi H, Ueno K, Ohta T, Kayahara M, Miyazaki I. Clinical study of lymphatic flow to the paraaortic lymph nodes in carcinoma of the head of the pancreas. Cancer 1994;73:1155-62.
59. Rosa JA, VanLinda BM, Abourizk MN. New onset diabetes as a harbinger of pancreatic carcinoma. J Clin Gastroenterol 1989;11:211-5.
60. Ishikawa O, Ohhigashi H, Wada A, Tateishi R, Ishiguro S, Okana Y, et al. Morphologic characteristics of pancreatic carcinoma with diabetes mellitus. Cancer 1989;64:1107-12.
61. Falconer JS, Fearson KCH, Plester CE, Ross JA, Carter DC. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994;219:325-31.
62. Campbell JP, Wilson SR. Pancreatic neoplasms: how useful is evaluation with ultrasound? Radiology 1988;167:341-4.
63. Shawker TH, Garra BS, Hill MC, Doppman JL, Sindelar WF. The spectrum of sonographic findings in pancreatic carcinoma. J Ultrasound Med 1986;5:169-177.
64. Laing FC, Jeffrey RB Jr., Wing VW, Nyberg DA. Biliary dilatation: defining the level and cause by real-time US. Radiology 1986;160:39-42.
65. Garra BS, Shawker TH, Doppman JL, Sindelar WF. Comparison of angiography and ultrasound in the evaluation of the portal venous system in pancreatic carcinoma. J Clin Ultrasound 1987;15:83-93.
66. Balthazar EJ, Chaco AC. Computed tomography of pancreatic masses. Am J Gastroenterol 1990;85:343-9.
67. Freeny PC, Marks WM, Ryan JA, Traverso LW. Pancreatic ductal adenocarcinoma: diagnosis and staging with dynamic CT. Rodiology 1988;166:125-33.
68. Freeny PC. Radiology of the pancreas: two decades of progress in imaging and intervention. Am J Roentgenol 1988; 150:975-81.
69. Megibow AJ. Pancreatic adenocarcinoma: designing the examination to evaluate the clinical questions. Radiology 1992;183:297-303.
70. Steiner E, Stack DD, Hahn PF, Saini S, Simeone JF, Mueller PR, et al. Imaging of pancreatic neoplasms: comparison of MR and CT. Am J Roentgenol 1989;152:487-9.
71. Muller MF, Meyenberger C, Bertschinger P, Schaer R, Marineck. Pancreatic tumors: evaluation with endoscopic US, CT, and MR imaging. Radiology 1994;190:745-52.
72. Endo Y, Morii J, Tamura N, Okuda S. Cytodiagnosis of pancreatic malignant tumors by aspiration, under direct vision, using a duodenal fiberscope. Gastroenterology 1974;67:944-51.
73. Venu RP, Greenen JE, Kini M, Hogan WJ, Payne M, Kohnson GK, et al. Endoscopic retrograde brush cytology: a new technique. Gastroenterology 1990;99:1475-9.
74. Scudera PL, Koizumi J, Jacobson IM. Brush cytology evaluation of lesions encountered during ERCP. Gastrointest Endosc 1990;36:281-4.
75. Miki H, Matsumoto S, Harada H, Mori S, Haba R, Ochi K, et al. Detection of c-Ki-ras point mutation from pancreatic juice. A useful diagnostic approach for pancreatic carcinoma. Int J Pancreatol 1993;14:145-8.
76. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350-5.
77. Frebourg T, Bercoff E, Manchon N, Senant J, Basuyau JP, Breton P, et al. The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer 1988;62:2287-90.
78. Tian F, Appert HE, Myles J, Howard JM. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg 1992;215:350-5.
79. Lundin J, Roberts PJ, Kuusela P, Haglund C. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer 1994;69:515-9.
80. Robles-Diaz G, Diaz-Sanchez V, Fernandez-del Castillo C. Serum testosterone: dihydrotestosterone ratio and CA 19-9 in the diagnosis of pancreatic cancer. Am J Gastroenterol 1991;86:591-4.
81. Al-Kaisi N, Siegler EE. Fine needle aspiration cytology of the pancreas. Acta Cytol 1989;33:145-52.
82. Parsons L, Palmer CH. How accurate is fine-needle biopsy in malignant neoplasia of the pancreas? Arch Surg 1989;124:681-3.
83. DelMaschio A, Vanzulli A, Sironi S, Castrucci M, Mellone R, Staudacher C, et al. Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy. Radiology 1991;178:95-9.
84. Paksoy N, Lilleng R, Hagmar B, Wetteland J. Diagnostic accuracy of fine needle aspiration cytology in pancreatic lesions. A review of 77 cases. Acta Cytol 1993;37:889-93.
85. Rashleigh-Belcher HJC, Russel RCG, Lees WR. Cutaneous seeding of pancreatic carcinoma by fine-needle aspiration biopsy. Br J Radiol 1986;59:182-3.
86. Ferrucci JT, Wittenberg J, Margolies MN, Carey RW. Malignant seeding of the tract after thin-needle aspiration biopsy. Radiology 1979;130:345-6.
87. Weiss SM, Skibber JM, Mohiuddin M, Rosato FE. Rapid intra-abdominal spread of pancreatic cancer. Influence of multiple operative biopsy procedures. Arch Surg 1985; 120:415-6.
88. Warshaw AL. Implications of peritoneal cytology for staging of early pancreatic cancer. Am J Surg 1991;161:26-30.
89. Worlock AJ, Zalutsky MR, Metzgar RS. Radiolocalization of human pancreatic carcinoma xenografts in nude mice by monoclonal antibody DU-PAN I. Cancer Res 1990;50:7246-51.
90. Tsuda T, Koshiba H, Usui T, Kubota M, Kikuchi K, Morita K. Radioimmunoscintigraphy of human pancreatic xenografts in nude mice with 131I-labelled monoclonal antibody. Ann Nucl Med 1990;4:71-4.
91. Takemoto T, Aibe T, Fuji T, Kita K. Endoscopic ultrasonography. Clin Gastroenterol 1986;15:305-19.
92. Kaufman AR, Sivak MV Jr. Endoscopic ultrasonography in the differential diagnosis of pancreatic disease. Gastrointest Endosc 1989;35:214-9.
93. Hayashi Y, Nakazawa S, Kimoto E, Naito Y, Morita K. Clinicogic analysis of endoscopic ultrasonograms in pancreatic mass lesions. Endoscopy 1989;21:121-5.
94. Warshaw AL, Tepper JE, Shipley WU. Laparoscopy in the staging and planning of therapy for pancreatic cancer. Am J Surg 1986;151:76-80.
95. Cuschieri A. Laparoscopy for pancreatic cancer: does it benefit the patient? Eur J Surg Oncol 1988;14:41-4.
96. Warshaw AL, Gu ZY, Wittenberg J, Waltman AC. Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg 1990;125:230-3.
97. Mackie CR, Noble HG, Cooper MJ, Collins P, Block GE, Moosa AR. Prospective evaluation of angiography in the diagnosis and management of patients suspected of having pancreatic cancer. Ann Surg 1979;189:11-17.
98. Mucondie JD, Nagpal S, Peebles SA. Surgical treatment for ductal adenocarcinoma of the pancreas. Surg Gynecol Obstet 1989;168:437-45.
99. Wanebo HJ, Koness RJ. Pancreatic cancer: surgical approach. In: Ahlgren JD, Macdonald JS, editors. Gastrointestinal oncology. Philadelphia: J.B. Lippincott, 1992:209-14.
100. Gudjonsson B. Cancer of the pancreas: 50 years of surgery. Cancer 1987;60:2284-2303.
101. Grace PA, Pitt HA, Tompkins RK, DenBesten L, Longmire WP Jr. Decreased morbidity and mortality after pancreatoduodenectomy. Am J Surg 1986;151:141-9.
102. Braasch JW, Deziel DJ, Rossi RL, Watkins E, Winter PF. Pyloric and gastric preserving pancreatic resection: experience with 87 patients. Ann Surg 1986;204:411-18.
103. Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality and survival after the Whipple procedure. Ann Surg 1987;206:358-65.
104. Edge SB, Schmieg RE Jr., Rosenlof LK, Wilhelm MC. Pancreas cancer resection outcome in American University centers in 1989-1990. Cancer 1993;71:3502-8.
105. Brooks JR, Brooks DC, Levine JD. Total pancreatectomy for dutal cell carcinoma of the pancreas. Ann Surg 1989; 209:405-10.
106. Pellegrini CA, Heck CF, Raper S, Way LW. An analysis of the reduced morbidity and mortality rates after pancreaticoduodenectomy. Arch Surg 1989;124:778-81.
107. Trede M, Schwall G, Saeger H-D. Survival after pancreatoduodenectomy. Ann Surg 1990;211:447-58.
108. Hannoun L, Christophe M, Ribeiro J, Nordlinger B, Elriwini M, Tiret E, et al. A report of forty-four instances of pancreaticoduodenal resection in patients more than seventy years of age. Surg Gynecol Obstet 1993;177:556-60.
109. Van Heerden JA. Carcinoma of the head of the pancreas: surgical options. In: Wanebo HJ, editor. Common problems in cancer surgery. Chicago: Year Book Medical Publishers, 1990:131-8.
110. Jordan GL Jr. Pancreatic resection for pancreatic cancer. Surg Clin North Am 1989;69:569-97.
111. Johnson CD, Schwail G, Flechtenmacher J, Trede M. Resection for adenocarcinoma of the body and tail of the pancreas. Br J Surg 1993;80:1177-9.
112. Dalton RR, Sarr MG, Van Heerden JA, Colby TV. Carcinoma of the body and tail of the pancreas: is curative resection justified? Surgery 1992;111:489-94.
113. Tryka AF, Brooks JR. Histopathology in the evaluation of total pancreatectomy for ductal carcinoma. Ann Surg 1979;190:373-81.
114. Pliam MB, Remine WH. Further evaluation of total pancreatectomy. Arch Surg 1975;110:506-12.
115. Ihse I, Ulja P, Arnesjo B, Bengmark S. Total pancreatectomy for cancer: an appraisal of 65 cases. Ann Surg 1977;186:675-80.
116. Van Heerden JA. Pancreatic resection for carcinoma of the pancreas: Whipple versus total pancreatectomy: an institutional perspective. World J Surg 1984;8:880-8.
117. Assan R, Alexandre JH, Tiengo A, Marre M, Costamailleres L, Lhomme C. Survival and rehabilitation after total pancreatectomy: a follow-up of 36 patients. Diabete Metab 1985;11:303-9.
118. Fortner JG. Regional pancreatectomy for cancer of the pancreas ampulla and other related sites. Tumor staging and results. Ann Surg 1984;199:418-25.
119. Ishikawa O, Ohhigashi H, Sasaki Y, Kabuto T, Fukuda I, Furukawa H, et al. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 1988;208:215-220.
120. Iskikawa O, Ohigashi H, Imaoka S, Furikawa H, Sasaki Y, Fujita M, et al. Preoperative indications for extended pancreatectomy for locally advanced pancreas cancer involving the portal vein. Ann Surg 1992;215:231-6.
121. Johnstone PA, Sindelar WF. Lymph node involvement and pancreatic resection: correlation with prognosis and local disease control in a clinical trial. Pancreas 1993;8:535-9.
122. Johnstone PA, Sindelar WF. Patterns of disease recurrence following definitive therapy of adenocarcinoma of the pancreas using surgery and adjuvant radiotherapy: correlations of a clinical trial. Int J Radiat Oncol Biol Phys 1993;27:831-4.
123. Grace PA, Pitt HA, Longmire WP. Pylorus preserving pancreatoduodenectomy: an overview. Br J Surg 1990;77:968-74.
124. Hinkenbijl JH, van der Schelling GP, Hop WC, van Pel R, Bruining HA, Jeekel J. The advantages of pylorus-preserving pancreatoduodenectomy in malignant disease of the pancreas and periampullary region. Ann Surg 1992;216:142-5.
125. Roder JD, Stein HJ, Huttl W, Siewert JR. Pylorus-preserving versus standard pancreatico-duodenectomy: an analysis of 110 pancreatic and periampullary carcinomas. Br J Surg 1992;79:152-5.
126. Sharp KW, Ross CB, Halter SA, Morrison JG, Richards WO, Williams LF, et al. Pancreatoduodenectomy with pyloric preservation for carcinoma of the pancreas: a cautionary note. Surgery 1989;105:645-53.
127. Bassi C, Falconi M, Lombardi D, Briani G, Vesentini S, Camboni MG, et al. Prophylaxis of complications after pancreatic surgery: results of a multicenter trial in Italy. Digestion Suppl 1994;1:41-7.
128. Sarr MG, Cameron JL. Surgical management for unresectable carcinoma of the pancreas. Surgery 1982;91:123-33.
129. Morrow M, Hilaris B, Brennan MF. Comparison of conventional surgical resection, radioactive implantation and bypass procedures for exocrine carcinoma of the pancreas. Ann Surg 1984;199:1-5.
130. Huibregtse K, Katon RM, Coene PP, Tytgat GN. Endoscopic palliative treatment in pancreatic cancer. Gastrointest Endosc 1986;32:334-8.
131. Soehendra N, Grimm H, Berger B, Nam VC. Malignant jaundice: results of diagnostic and therapeutic endoscopy. World J Surg 1989;13:171-7.
132. Cotton PB. Nonsurgical palliation of jaundice in pancreatic cancer. Surg Clin North Am 1989;69:613-27.
133. Andersen JR, Sorensen SM, Kruse A, Rokkjaer M, Matzen P. Randomized trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. Gut 1989;30:1132-5.
134. Watanapa P, Williamson RCN. Surgical palliation for pancreatic cancer: developments during the past two decades. Br J Surg 1992;79:8-20.
135. Sing SM, Reber HA. Surgical palliation for pancreatic cancer. Surg Clin North Am 1989;69:599-611.
136. Weaver DW, Wiencek RG, Bouwman DL, Watt AJ. Gastrojejunostomy: is it helpful for patients with pancreatic cancer? Surgery 1987;102:608-13.
137. Doberneck RC, Berndt GA. Delayed gastric emptying after palliative gastrojejunostomy for carcinoma of the pancreas. Arch Surg 1987;122:827-9.
138. Wade TP, Radford DM, Virgo KS, Johnson FE. Complications and outcomes in the treatment of pancreatic adenocarcinoma in the United States veteran. J Am Coll Surg 1994;179:38-48.
139. Lillemoe KD, Cameron JL, Kaufman HS, Yeo CJ, Pitt HA, et al. Chemical splanchnicetomy in patients with unresectable pancreatic cancer. A prospective randomized trial. Ann Surg 1993;217:456-7.
140. Leung JW, Bowen-Wright M, Aveling W, Shorvon PJ, Cotton PB. Coeliac plexus block for pain in pancreatic cancer and chronic pancreatitis. Br J Surg 1983;70:730-2.
141. Sastre B, Carabalona B, Crespy B, Delpero JR, Sielezneff I, Michotey G. Transhiatal bilateral splanchnicotomy for pain control in pancreatic cancer: basic anatomy, surgical technique, and immediate results in fifty-one cases. Surgery 1992;111:640-6.
142. Harter WK. Pancreatic cancer: radiotherapeutic approaches. In: Ahlgren JD, McDonald JS, editors. Gastrointestinal Oncology. Philadelphia: JB Lippincott, 1992:215-25.
143. Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903.
144. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987;59:2006-10.
145. Whitington R, Solin L, Mohiuddin M, Cantor RI, Rosato FE, Bierman WA, et al. Multimodality therapy of localized unresectable pancreatic adenocarcinoma. Cancer 1984;54:1991-8.
146. Dobelbower RR Jr, Konski AA, Merrick HW 3rd, Bronn DG, Schifeling D, Kamen C. Intraoperative electron beam radiation therapy (IOEBRT) for carcinoma of the exocrine pancreas. Int J Radiat Oncol Biol Phys 1991;20:113-9.
147. Wood WC, Shipley WU, Gunderson LL, Cohen AM, Nardi GL. Intraoperative irradiation for unresectable pancreatic carcinoma. Cancer 1982;49:1272-5.
148. Shipley WU, Wood WC, Tepper JE, Warshaw AL, Orlow EL, Kaufman SD, et al. Intraoperative electron beam irradiation for patients with unresectable pancreatic carcinoma. Ann Surg 1984;200:289-96.
149. Abe M, Takahashi M. Intraoperative radiotherapy: the Japanese experience. Int J Radiat Oncol Biol Phys 1981;7:863-8.
150. Shipley WU, Nardi GL, Cohen AM, Ling CC. Iodine-125 implant and external beam irradiation in patients with localized pancreatic carcinoma: a comparative study to surgical resection. Cancer 1980;45:709-14.
151. Joyce F, Burcharth F, Holm HH, Stroyer I. Ultrasonically guided percutaneous implantation of Iodine-125 seeds in pancreatic carcinoma. Int J Radiat Oncol Biol Phys 1990;19:1049-62.
152. Merrick HW 3rd, Dobelbower RR Jr. Aggressive therapy for cancer of the pancreas: does it help? Gastroenterol Clin North Am 1990;19:935-62.
153. Mohiuddin M, Rosato F, Schuricht A, Barbot D, Bierman W, Cantor R. Carcinoma of the pancreas - the Jefferson experience 1975-1988. Eur J Surg Oncol 1994;20:13-20.
154. Nishimura A, Nakano M, Otsu H, Nakano K, Iida K, Sakata S, et al. Intraoperative radiotherapy for advanced carcinoma of the pancreas. Cancer 1984;54:2375-84.
155. Ahlgren J. Pancreatic cancer: chemotherapy of advanced disease. In: Ahlgren JD, MacDonald JS, editors. Gastrointestinal oncology. Philadelphia: J.B. Lippincott, 1993:227-35.
156. Carter SK, Comis L. The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev 1975;2:193-214.
157. Schein PS, Lavin PT, Moertel CG, Hahn RG, O'Connell MJ, Reitemeier RJ, et al. Randomized Phase II clinical trial of adriamycin, methotrexate and actinomycin-D in advanced measurable pancreatic carcinoma: a Gastrointestinal Tumor Study Group Report. Cancer 1978;42:19-22.
158. Gastrointestinal Tumor Study Group. Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. Cancer 1989;64:2010-3.
159. Mallinson CN, Rake MO, Cocking JB. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicenter trial. BMJ 1980;281:1589-91.
160. Cullinan S, Moertel CG, Wieand HS, Schutt AJ, Krook JE, Foley JF, et al. A Phase III trial of the therapy of advanced pancreatic adenocarcinoma. Evaluations of Mallinson regimen and combined 5-Fluorouricil, Doxorubicin, and Cisplatin. Cancer 1990;65:2207-12.
161. Zalatnai A, Schally AV. Treatment of N-nitrosobis (2-oxopropyl) amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and a somatostatin analog RC-160. Cancer Res 1989;49:1810-5.
162. Szende B, Zolatnai A, Schally AV. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both leuteinizing hormone-releasing hormone and somatostatin. Proc Natl Acad Sci USA 1989;86:1643-7.
163. Szende B, Srkalovic G, Schally AV, Lapis K, Groot K. Inhibitory effects of analogs of leuteinizing hormone-releasing hormone and somatostatin on pancreatic cancer in hamsters: events that accompany tumor regression. Cancer 1990;65:2279-90.
164. Keating JJ, Johnson PJ, Cochrane AM, Gazzard BG, Krasner N, Smith PM, et al. A prospective randomized controlled trial of tamoxifen therapy and cyproterone acetate in pancreatic carcinoma. Br J Cancer 1989;60:789-92.
165. Bakkevold KE, Pettersen A, Arnesjo B, Espehaug B. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater. Br J Surg 1990;77:725-30.
166. Schally AV. Oncological applications of somatostatin analogs. Cancer Res 1988;48:6977-85.
167. Mang TS, Weiman TJ. Photodynamic therapy in the treatment of pancreatic carcinoma: dihematoporphyrin ether uptake and photobleaching kinetics. Photochem Photobiol 1987;46:853-8.
168. Schroder T, Chen IW, Sperling M, Bell RH Jr., Brackett K, Joffe SN. Hematoporphyrin derivative uptake and photodynamic therapy in pancreatic carcinoma. J Surg Oncol 1988;38:4-9.
169. Mehta MP, Kubsad SS, Fowler IF, Verna AK, Hsieh JT, Kinsella TJ. 90Y.B72.3 against pancreatic cancer: dosimetric and biological analysis. Int J Radiat Oncol Biol Phys 1990;19:627-31.
170. Tempero MA, Sivinski C, Steplewski Z. Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biological and clinical effects. J Clin Oncol 1990;8:2019-26.
171. Knuth A, Bernhard H, Klein O, Meyer zum Buschenfelde KH. Combination fluorouracil, folinic acid and Interferon alfa-2a: an active regimen in advanced pancreatic carcinoma. Semin Oncol 1992;19 (Suppl 3):211-4.
172. Ozaki H, Hojo K, Kato H, Kinoshita T, Egawa S, Kishi K. Multidisciplinary treatment for resectable pancreatic cancer. Int J Pancreatol 1988;3:249-60.
173. Hoffman JP, Weese JL, Solin LJ, Engstrom P, Agarwal P, Barber LW, et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg 1995;169:71-7.
174. Tyler DS, Evans DB. Reoperative pancreaticodeodenectomy. Ann Surg 1994;219:211-21.
175. Turk PS, Wanebo HJ, Glicksman AS, Clark J, Koness RJ. Multimodality protocol for locally advanced carcinoma of the pancreas: pilot program. Proc Am Soc Clin Oncol 1992;11:564.
176. Launois B, Franci J, Bardoxoglou E, Ramee MP, Paul JL, Malledant Y, et al. Total pancreatectomy for ductal adenocarcinoma of the pancreas with special reference to resection of the portal vein and multicentric cancer. World J Surg 1993;17:122-7.
177. Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I. Pancreatic resection for periampullary carcinoma in the elderly. Surg Today 1994;24:229-33.
178. Takada T. Pylorous preserving pancreaticoduodenectomy technique and indications. Hepatogastroentemlogy 1993; 40:422-5.
179. Tsao JI, Rossi RL, Lowell JA. Pylorous preserving pancreatectomy: is it an adequate cancer operation. Arch Surg 1994;129:405-12.
180. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995;221:721-33.
181. Willet GC, Lewanrowski K, Warshaw AL, Efird J, Compton CC. Resection margins in carcinoma of the head of the pancreas. Ann Surg 1993;217:144-8.